[1] Rouas-Freiss N. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis[J]. Proc Natl Acad Sci U S A,1997,94(21):11520-11525.
[2] Brannstrm M, Johannesson L, Bokstrm H, et al. Livebirth after uterus transplantation[J].Lancet,2015,385(9968):607-616.
[3] Brannstrm M, Johannesson L. First clinical uterus transplantationtrial: a six-month report[J]. Fert steril,2014,101(5):1228-1236.
[4] Rouas-Freiss N. HLA-G in transplantation: a relevant molecule for inhibition of graft rejection?[J]. Am J Transplant,2003,3(1):11-16.
[5] Carosella E D. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance[J]. Adv Immunol,2003,81:199-252.
[6] Favier B, LeMaoult J, Lesport E, et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse[J]. FASEB J,2010,24(3):689-699.
[7] Carosella E D, Favier B, Rouas-Freiss N, et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule[J]. Blood,2008, 111(10):4862-4870.
[8] Naji A,Menier C,Morandi F,et al.Binding of HLA-G to ITIM bearing Ig—like transcript 2 receptor suppresses B cell responses[J].J lmmunol,2014(192):1536-1546.
[9] Bahri R, Hirsch F, Josse A,et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes[J]. J Immunol,2006,176(3):1331-1339.
[10] Lila N, Rouas-Freiss N, Dausset J, et al. Soluble HLA-G protein secreted by allo-specific CD4⁺ T cells suppresses the allo-proliferative response: a CD4⁺ T cell regulatory mechanism[J]. Proc Natl Acad Sci U S A,2001,98(21):12150-12155.
[11] Kapasi K, Albert S E, Yie S, et al. HLA-G has a concentration-dependent effect on the generation of the allo-CTL response[J]. Immunology,2000,101(2):191-200.
[12] Sasaki H, Xu X C,Smith D M, et al. HLA-G expression protects porcine endothelial cells against natural killer cellmediated xenogeneic cytotoxicity[J]. Transplantation,1999(67):31-36.
[13] Gregori S,Tomasoni D,Paeeiani V,et al.Differentiation of type 1 T regulatory eeUs(Trl)by tolemgenic DC·10 requires the IL-10 dependent ILT4／HLA-G pathway[J].Blood,2010,1(16):935-944.
[14] Ristich V, Liang S,Zhang W,et al. Tolerization of dendritic cells by HLA-G[J]. Eur J Immunol,2005,35(4):1133-1142.
[15] Amodio G,Comi M,Tomasoni D,et al. HLA-G expression levels influence the tolerogenic activity of human DC-10[J]. Haematologica,2015,100(4):548-557.
[16] Amodio G,Sales de Albuquerque R,Gregori S. New in sight into HLA-G mediated tolerance[J].Tissue Antigens,2014,84(3): 255-263.
[17] Lila N, Carpentier A, Amrein C, et al. Implication of HLA-G molecule in heart-graft acceptance[J]. Lancet,2000,355 (9221):2138.
[18] Lila N, Amrein C Guillemain R,et al. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejection after heart transplantation[J]. J Heart Lung Transplant,2007,6(9):2152-2156.
[19] Juch H. A novel sandwich ELISA for a1 domain based detection of soluble HLA-G heavy chains[J]. J Immunol Methods,2005,307(1-2):96-106.
[20] Lila N, Amrein C. human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection[J]. Circulation,2002,105(16):1949-1954.
[21] Sheshgiri R, Rous-Freiss N, Rao, et al. Myocardial HLA-G reliably indicates a low risk of acute cellular rejection in heart transplant recipients[J]. J Heart Lung Transplant,2008,27(5):522-527.